Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 6/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.45 |
| ▸ | CACNA1I | Q9P0X4 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284013 | 0.85 | HTT (0.55) | ADRB2ADRB1L3MBTL1HPGDHTT | |
| SCHEMBL26725046 | 0.84 | L3MBTL1 (0.64) | ADRB2ADRB1L3MBTL1CACNA1GCACNA1H | |
| SCHEMBL8081119 | 0.84 | L3MBTL1 (0.55) | ADRB2ADRB1L3MBTL1CACNA1GCACNA1H | |
| SCHEMBL10963108 | 0.83 | TDP1 (0.46) | ADRB2ADRB1L3MBTL1HPGDHTT | |
| SCHEMBL7847681 | 0.82 | TSHR (0.58) | L3MBTL1KDM4ELMNAPPARD | |
| SCHEMBL30104114 | 0.82 | TSHR (0.58) | L3MBTL1KDM4ELMNAPPARD | |
| SCHEMBL18066342 | 0.81 | L3MBTL1 (0.47) | L3MBTL1KDM4EPPARD | |
| SCHEMBL12400302 | 0.81 | ALDH1A1 (0.49) | L3MBTL1HPGDHTTKDM4ELMNA | |
| SCHEMBL22442208 | 0.80 | L3MBTL1 (0.51) | ADRB2ADRB1L3MBTL1CACNA1GCACNA1H | |
| SCHEMBL30027909 | 0.80 | MEN1 (0.58) | L3MBTL1HPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| CN-101284865-A | Novel compound and medical use thereof | TOYAMA CHEMICAL CO LTD (JP) | 2008-10-15 | — | — | CN | disclosed |
| CN-100378063-C | Novel compound and medical use thereof | TOYAMA CHEMICAL CO LTD (JP) | 2008-04-02 | — | — | CN | disclosed |
| US-7314888-B1 | Compounds and medicinal use thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| CN-1325376-A | Novel compound and medical use thereof | TOYAMA CHEMICAL CO LTD (JP) | 2001-12-05 | — | — | CN | disclosed |
| EP-1127869-A1 | NOVEL COMPOUNDS AND MEDICINAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SP1, AP1G1, AP1M1 | ADRB2 1988/4885ADRB1 1131/4885HTR1A 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.